Fred Yang

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Julio Rosenstock, Jane E.B. Reusch, Mark Bush et al. · Diabetes Care · 2009 · 236 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Åhrén, Susan Johnson, Murray Stewart et al. · Diabetes Care · 2014 · 226 citations

Medicine, Pharmacology, Pharmacotherapy +16

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross et al. · Diabetes Care · 2014 · 205 citations

Medicine, Endocrinology, Pharmacotherapy +17

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Michael A. Nauck, Murray Stewart, Christopher Perkins et al. · Diabetologia · 2015 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Lawrence A. Leiter, Molly C. Carr, Murray Stewart et al. · Diabetes Care · 2014 · 91 citations

Medicine, Pharmacology, Pharmacotherapy +17